First Ascent Biomedical
First Ascent Biomedical creates personalized cancer treatment plans by testing how a patient’s tumor and resistant cells respond to drugs and using AI to rank effective options. Their Drug Prediction Platform (DxPP) uses a proprietary cell enrichment method to grow tumor bulk and chemo‑resistant cells, performs drug sensitivity testing across hundreds of FDA‑approved drugs, and integrates DNA/RNA sequencing, mutation analysis, and causal machine learning to generate combination and monotherapy recommendations. The company operates as a biotech platform serving oncology physicians and patients with actionable reports delivered in about 10 days. First Ascent supports clinical and drug‑development workflows and partners with cancer centers and industry for validation studies and sponsored research.
First Ascent Biomedical
First Ascent Biomedical creates personalized cancer treatment plans by testing how a patient’s tumor and resistant cells respond to drugs and using AI to rank effective options. Their Drug Prediction Platform (DxPP) uses a proprietary cell enrichment method to grow tumor bulk and chemo‑resistant cells, performs drug sensitivity testing across hundreds of FDA‑approved drugs, and integrates DNA/RNA sequencing, mutation analysis, and causal machine learning to generate combination and monotherapy recommendations. The company operates as a biotech platform serving oncology physicians and patients with actionable reports delivered in about 10 days. First Ascent supports clinical and drug‑development workflows and partners with cancer centers and industry for validation studies and sponsored research.